IFNG and colorectal neoplasm: After demonstrating that pharmacologically active levels of both bispecific antibodies could be achieved by i.v. mRNA-LNP administration, we investigated their antitumor activity in an immunocompetent mouse model subcutaneously xenografted with CT26EGFR colorectal tumors (10, 22), which constitutively expresses low levels of PD-L1 that increase in response to soluble IFNγ (Supplementary Figure 10).